Microphysiological Systems: Stakeholder Challenges to Adoption in Drug Development
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Microphysiological systems (MPS) or tissue chips/organs-on-chips are novel in vitro models that emulate human physiology at the most basic functional level. In this review, we discuss various hurdles to widespread adoption of MPS technology focusing on issues from multiple stakeholder sectors, e.g., academic MPS developers, commercial suppliers of platforms, the pharmaceutical and biotechnology industries, and regulatory organizations. Broad adoption of MPS technology has thus far been limited by a gap in translation between platform developers, end-users, regulatory agencies, and the pharmaceutical industry. In this brief review, we offer a perspective on the existing barriers and how end-users may help surmount these obstacles to achieve broader adoption of MPS technology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A practical guide to hydrogels for cell culture
Caliari, S. R., & Burdick, J. A. (2016) · Nature Methods · doi:10.1038/nmeth.3839 · Cited by 2,075
An analysis of the attrition of drug candidates from four major pharmaceutical companies
Waring, M. J., Arrowsmith, J., Leach, A. R., Leeson, P. D., Mandrell, S., Owen, R. M., Pairaudeau, G., Pennie, W. D., Pickett, S. D., Wang, J., et al. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4609 · Cited by 1,450
Kim, H. J., Li, H., Collins, J. J., & Ingber, D. E. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522193112 · Cited by 922
Instrumented cardiac microphysiological devices via multimaterial three-dimensional printing
Lind, J. U., Busbee, T. A., Valentine, A. D., Pasqualini, F. S., Yuan, H., Yadid, M., Park, S.-J., Kotikian, A., Nesmith, A. P., Campbell, P. H., et al. (2017) · Nature Materials · doi:10.1038/nmat4782 · Cited by 863
Wang, G., McCain, M. L., Yang, L., He, A., Pasqualini, F. S., Agarwal, A., Yuan, H., Jiang, D., Zhang, D., Zangi, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3545 · Cited by 837
Phase II and Phase III attrition rates 2011–2012
Arrowsmith, J., & Miller, P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4090 · Cited by 697 · cited 2×
“…and therapeutics is largely due to high attrition rate of candidate therapies due to compound toxicity in early preclinical stages and lack of efficacy in later clinical stages [Arrowsmith, 2011a; Arrowsmith, 2011b; Arrowsmith and Miller, 2013; Jardim et al., 2017; Parasrampuria et al., 2018].”
BackgroundOrgans-on-a-Chip: A Fast Track for Engineered Human Tissues in Drug Development
Ronaldson-Bouchard, K., & Vunjak-Novakovic, G. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.02.011 · Cited by 657 · cited 5×
“These attributes allow MPS to accurately recapitulate many key aspects of human organ structure and function, including biochemical and physiochemical microenvironmental cues, vascular perfusion, microfluidic flow, human organ innervation, and proper establishment of growth hormone gradients, cytokines, and other sign…”
BackgroundMethodInfluentialArrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Reproducing human and cross-species drug toxicities using a liver-chip
Jang, K.-J., Otieno, M. A., Ronxhi, J., Lim, H.-K., Ewart, L., Kodella, K. R., Petropolis, D. B., Kulkarni, G., Rubins, J. E., Conegliano, D., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aax5516 · Cited by 511
Small molecule absorption by PDMS in the context of drug response bioassays
van Meer, B. J., de Vries, H., Firth, K. S. A., van Weerd, J., Tertoolen, L. G. J., Karperien, H. B. J., Jonkheijm, P., Denning, C., IJzerman, A. P., & Mummery, C. L. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.11.062 · Cited by 502 · cited 1×
“Additionally, researchers have developed novel chemical methods to improve PDMS qualities, such as development of coatings to reduce the surface permeability [van Meer et al., 2017].”
Interconnected Microphysiological Systems for Quantitative Biology and Pharmacology Studies
Edington, C. D., Chen, W. L. K., Geishecker, E., Kassis, T., Soenksen, L. R., Bhushan, B. M., Freake, D., Kirschner, J., Maass, C., Tsamandouras, N., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-22749-0 · Cited by 487
Organ-on-a-chip devices advance to market
Zhang, B., & Radisic, M. (2017) · Lab on a Chip · doi:10.1039/c6lc01554a · Cited by 437
Personalised organs-on-chips: functional testing for precision medicine
van den Berg, A., Mummery, C. L., Passier, R., & van der Meer, A. D. (2019) · Lab on a Chip · doi:10.1039/c8lc00827b · Cited by 270 · cited 1×
“1c) [van den Berg et al., 2019].”
Paek, J., Park, S. E., Lu, Q., Park, K.-T., Cho, M., Oh, J. M., Kwon, K. W., Yi, Y.-S., Song, J. W., Edelstein, H. I., et al. (2019) · ACS Nano · doi:10.1021/acsnano.9b00686 · Cited by 238 · cited 1×
“…[Lind et al., 2017a; Lind et al., 2017b; Stein et al., 2020], liver [Li et al., 2018; Ribeiro et al., 2019], vasculature [Herron et al., 2019; Paek et al., 2019], kidney [Maass et al., 2019; Chapron et al., 2020; Phillips et al., 2020; Sakolish et al., 2020], skin [Hardwick et al., 2020; Kim…”
BackgroundBaudy, A. R., Otieno, M. A., Hewitt, P., Gan, J., Roth, A., Keller, D., Sura, R., Van Vleet, T. R., & Proctor, W. R. (2020) · Lab on a Chip · doi:10.1039/c9lc00768g · Cited by 150 · cited 5×
“The IQ MPS Affiliate also stress the importance in development of animal MPS models of relevant preclinical species currently used in tox analyses (rat, dog, rhesus), which will help bolster end-user confidence in the fidelity of each platform [Baudy et al., 2020].”
BackgroundMethodInfluentialBarrile, R., van der Meer, A. D., Park, H., Fraser, J. P., Simic, D., Teng, F., Conegliano, D., Nguyen, J., Jain, A., Zhou, M., et al. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1054 · Cited by 138 · cited 1×
“For example, a human blood vessel MPS was able to reproduce the thrombotic toxicities noted in patients treated with a novel monoclonal antibody therapeutic even though such toxicity was never noted in preclinical animal models [Barrile et al., 2018].”
BackgroundFabre, K., Berridge, B., Proctor, W. R., Ralston, S., Will, Y., Baran, S. W., Yoder, G., & Van Vleet, T. R. (2020) · Lab on a Chip · doi:10.1039/c9lc01168d · Cited by 116
Fowler, S., Chen, W. L. K., Duignan, D. B., Gupta, A., Hariparsad, N., Kenny, J. R., Lai, W. G., Liras, J., Phillips, J. A., & Gan, J. (2020) · Lab on a Chip · doi:10.1039/c9lc00857h · Cited by 109
Ekert, J. E., Deakyne, J., Pribul-Allen, P., Terry, R., Schofield, C., Jeong, C. G., Storey, J., Mohamet, L., Francis, J., Naidoo, A., et al. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220923332 · Cited by 68 · cited 2×
“Additionally, extinguishing the competitive mindset in pharma, and increasing the amount of data sharing and additional pre-competitive activities, will help promote technological adoption [Ewart and Roth, 2020].”
BackgroundAinslie, G. R., Davis, M., Ewart, L., Lieberman, L. A., Rowlands, D. J., Thorley, A. J., Yoder, G., & Ryan, A. M. (2019) · Lab on a Chip · doi:10.1039/c9lc00492k · Cited by 65 · cited 1×
“…including the kidney, liver, skin, lung, cardiovascular, blood-brain barrier, and gastrointestinal systems, as well as for ADME applications [Ainslie et al., 2019; Baudy et al., 2020; Fabre et al., 2020; Fowler et al., 2020; Hardwick et al., 2020; Peters et al., 2020; Peterson et al., 2020;…”
Background
Cited by
Human organs-on-chips for disease modelling, drug development and personalized medicine
Ingber, D. E. (2022) · Nature Reviews Genetics · doi:10.1038/s41576-022-00466-9 · Cited by 1,589
A guide to the organ-on-a-chip
Leung, C. M., de Haan, P., Ronaldson-Bouchard, K., Kim, G.-A., Ko, J., Rho, H. S., Chen, Z., Habibovic, P., Jeon, N. L., Takayama, S., et al. (2022) · Nature Reviews Methods Primers · doi:10.1038/s43586-022-00118-6 · Cited by 1,116
The evolving role of investigative toxicology in the pharmaceutical industry
Pognan, F., Beilmann, M., Boonen, H. C. M., Czich, A., Dear, G., Hewitt, P., Mow, T., Oinonen, T., Roth, A., Steger-Hartmann, T., et al. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00633-x · Cited by 255
Roadblocks confronting widespread dissemination and deployment of Organs on Chips
Alver, C. G., Drabbe, E., Ishahak, M., & Agarwal, A. (2024) · Nature Communications · doi:10.1038/s41467-024-48864-3 · Cited by 74
“However, Organ on Chip platforms face many technical and regulatory barriers that may complicate their widespread adoption in industrial use, and in pre-clinical trials 50 .”
Microphysiological Systems Evaluation: Experience of TEX-VAL Tissue Chip Testing Consortium
Rusyn, I., Sakolish, C., Kato, Y., Stephan, C., Vergara, L., Hewitt, P., Bhaskaran, V., Davis, M., Hardwick, R. N., Ferguson, S. S., et al. (2022) · Toxicological Sciences · doi:10.1093/toxsci/kfac061 · Cited by 43
Metadata
- Authors
- Hargrove-Grimes, P., Low, L. A., & Tagle, D. A.
- Venue
- Cells Tissues Organs
- Publisher
- S. Karger AG
- Published
- 2021-08-11
- Volume
- 211
- Issue
- 3
- Pages
- 269-281
- ISSN
- 1422-6405 (ISSN-L)
- 1422-6421
- OpenAlex
- W3191973919
- Cited by
- 48
- References
- 20
- FWCI
- 1.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.